| Min Pa: | Min Pa(max): | Activity's type: |
| Ext | Pa | Pi | Pmax | Activity | Other Results | ID Pa_max |
|---|---|---|---|---|---|---|
| 0.927 | 0.003 | 0.927 | Anticonvulsant | 0.746 0.005 DBMET00395 0.88 0.004 DBMET00396 | ||
| 0.911 | 0.003 | 0.911 | Platelet aggregation inhibitor | 0.869 0.004 DBMET00395 0.836 0.004 DBMET00396 | ||
| 0.9 | 0.003 | 0.9 | Platelet activating factor antagonist | 0.842 0.003 DBMET00395 0.776 0.004 DBMET00396 | ||
| 0.884 | 0.001 | 0.884 | Benzodiazepine agonist | 0.676 0.002 DBMET00395 0.561 0.002 DBMET00396 | ||
| 0.812 | 0.002 | 0.812 | GABA A receptor antagonist | 0.583 0.003 DBMET00395 0.655 0.003 DBMET00396 | ||
| 0.808 | 0.002 | 0.808 | GABA receptor agonist | 0.664 0.003 DBMET00395 0.714 0.003 DBMET00396 | ||
| 0.802 | 0.002 | 0.802 | GABA receptor antagonist | 0.569 0.003 DBMET00395 0.666 0.003 DBMET00396 | ||
| 0.687 | 0.004 | 0.687 | GABA C receptor rho-3 antagonist | 0.565 0.012 DBMET00395 0.556 0.013 DBMET00396 | ||
| 0.67 | 0.005 | 0.682 | Psychostimulant | 0.527 0.009 DBMET00395 0.682 0.005 DBMET00396 | DBMET00396 | |
| 0.406 | 0.004 | 0.406 | Vasopressin 1 antagonist | 0.108 0.008 DBMET00395 0.321 0.004 DBMET00396 | ||
| 0.383 | 0.004 | 0.383 | GABA A receptor agonist | 0.102 0.035 DBMET00395 0.278 0.005 DBMET00396 | ||
| 0.476 | 0.098 | 0.514 | Antiinflammatory | 0.514 0.082 DBMET00396 | DBMET00396 | |
| 0.341 | 0.003 | 0.341 | Vasopressin 1A antagonist | 0.086 0.006 DBMET00395 0.249 0.004 DBMET00396 | ||
| 0.34 | 0.004 | 0.34 | Antidiuretic hormone antagonist | 0.121 0.009 DBMET00395 0.277 0.004 DBMET00396 | ||
| 0.302 | 0.004 | 0.302 | Bromodomain-containing protein 4 inhibitor | 0.205 0.005 DBMET00395 0.094 0.014 DBMET00396 | ||
| 0.277 | 0.008 | 0.277 | GABA C receptor rho-2 antagonist | 0.208 0.025 DBMET00395 0.201 0.028 DBMET00396 | ||
| 0.262 | 0.005 | 0.262 | Interleukin 2 antagonist | 0.197 0.008 DBMET00395 0.132 0.031 DBMET00396 | ||
| 0.245 | 0.002 | 0.245 | Bromodomain-containing protein 3 inhibitor | 0.211 0.003 DBMET00395 0.108 0.005 DBMET00396 | ||
| 0.279 | 0.05 | 0.279 | Cyclic AMP phosphodiesterase inhibitor | 0.163 0.132 DBMET00395 0.163 0.132 DBMET00396 | ||
| 0.222 | 0.004 | 0.222 | Oxytocin antagonist | 0.124 0.008 DBMET00395 0.213 0.004 DBMET00396 | ||
| 0.217 | 0.003 | 0.217 | Bromodomain-containing protein 2 inhibitor | 0.159 0.007 DBMET00395 0.124 0.02 DBMET00396 | ||
| 0.179 | 0.02 | 0.179 | Pregnane X receptor agonist | 0.149 0.055 DBMET00395 0.153 0.048 DBMET00396 | ||
| 0.181 | 0.032 | 0.181 | Glutamate receptor antagonist | 0.169 0.039 DBMET00396 | ||
| 0.135 | 0.006 | 0.135 | Phosphodiesterase II inhibitor | 0.066 0.026 DBMET00395 0.099 0.011 DBMET00396 | ||
| 0.127 | 0.003 | 0.127 | Benzodiazepine antagonist | 0.075 0.005 DBMET00395 0.07 0.007 DBMET00396 | ||
| 0.126 | 0.006 | 0.126 | Phosphodiesterase 2A inhibitor | 0.059 0.025 DBMET00395 0.09 0.011 DBMET00396 | ||
| 0.14 | 0.026 | 0.14 | GABA C receptor rho-1 antagonist | 0.094 0.07 DBMET00395 0.104 0.057 DBMET00396 | ||
| 0.114 | 0.006 | 0.114 | Nicotinic acid receptor 1 agonist | 0.08 0.011 DBMET00395 0.048 0.022 DBMET00396 | ||
| 0.106 | 0.008 | 0.106 | Cholecystokinin A antagonist | 0.047 0.02 DBMET00396 | ||
| 0.16 | 0.065 | 0.16 | Heat shock protein 90 antagonist | |||
| 0.137 | 0.043 | 0.137 | MAP kinase 13 inhibitor | 0.124 0.052 DBMET00395 | ||
| 0.132 | 0.042 | 0.132 | GABA C receptor antagonist | 0.1 0.078 DBMET00396 | ||
| 0.125 | 0.036 | 0.125 | Hedgehog signaling inhibitor | |||
| 0.12 | 0.037 | 0.12 | Phosphodiesterase 7B inhibitor | 0.084 0.08 DBMET00395 | ||
| 0.091 | 0.009 | 0.091 | Cholecystokinin antagonist | 0.048 0.026 DBMET00396 | ||
| 0.198 | 0.121 | 0.198 | Cardiotonic | |||
| 0.089 | 0.011 | 0.089 | Corticotropin releasing factor 2 receptor antagonist | |||
| 0.169 | 0.096 | 0.279 | Anesthetic general | 0.279 0.039 DBMET00395 0.15 0.113 DBMET00396 | DBMET00395 | |
| 0.096 | 0.023 | 0.096 | Purinergic P2 antagonist | |||
| 0.129 | 0.058 | 0.129 | Cholesterol synthesis inhibitor | 0.11 0.075 DBMET00395 0.116 0.068 DBMET00396 | ||
| 0.083 | 0.012 | 0.083 | Purinergic P2X antagonist | |||
| 0.068 | 0.008 | 0.068 | Purinergic P2X7 antagonist | 0.033 0.028 DBMET00396 | ||
| 0.128 | 0.075 | 0.128 | Sodium channel (voltage-gated) blocker | 0.121 0.083 DBMET00396 | ||
| 0.072 | 0.02 | 0.072 | AMPA receptor antagonist | 0.051 0.031 DBMET00395 0.063 0.023 DBMET00396 | ||
| 0.085 | 0.033 | 0.086 | GABA B receptor agonist | 0.073 0.058 DBMET00395 0.086 0.031 DBMET00396 | DBMET00396 | |
| 0.241 | 0.191 | 0.241 | Analgesic | |||
| 0.074 | 0.025 | 0.074 | Phosphodiesterase 1C inhibitor | 0.058 0.053 DBMET00396 | ||
| 0.054 | 0.005 | 0.054 | Corticotropin releasing factor 1 receptor antagonist | 0.026 0.012 DBMET00395 0.022 0.016 DBMET00396 | ||
| 0.085 | 0.037 | 0.085 | Protein kinase B beta inhibitor | 0.084 0.038 DBMET00395 | ||
| 0.069 | 0.025 | 0.069 | Phosphodiesterase 1A inhibitor | |||
| 0.095 | 0.054 | 0.095 | Potassium channel activator | |||
| 0.098 | 0.059 | 0.098 | DNA directed RNA polymerase inhibitor | |||
| 0.061 | 0.022 | 0.061 | Glutamate (mGluR5) antagonist | |||
| 0.056 | 0.017 | 0.056 | Benzodiazepine inverse agonist | 0.051 0.025 DBMET00396 | ||
| 0.051 | 0.014 | 0.051 | Vasopressin 2 antagonist | 0.032 0.024 DBMET00396 | ||
| 0.044 | 0.01 | 0.082 | Benzodiazepine receptor peripheral-type antagonist | 0.082 0.004 DBMET00395 0.034 0.023 DBMET00396 | DBMET00395 | |
| 0.133 | 0.105 | 0.133 | MAP kinase kinase 4 inhibitor | 0.129 0.117 DBMET00395 | ||
| 0.047 | 0.021 | 0.047 | Alpha 1L adrenoreceptor agonist | 0.04 0.039 DBMET00396 | ||
| 0.201 | 0.176 | 0.201 | Antithrombotic | |||
| 0.071 | 0.047 | 0.071 | Glutamate (mGluR group I) antagonist | |||
| 0.077 | 0.052 | 0.077 | Glutamate (mGluR) antagonist | |||
| 0.047 | 0.026 | 0.047 | Parathyroid hormone antagonist | 0.045 0.032 DBMET00396 | ||
| 0.061 | 0.04 | 0.061 | Phosphodiesterase 1B inhibitor | |||
| 0.045 | 0.026 | 0.045 | GABA B receptor antagonist | 0.04 0.035 DBMET00396 | ||
| 0.068 | 0.049 | 0.068 | MAP kinase kinase 8 inhibitor | |||
| 0.271 | 0.254 | 0.271 | Ca2+/calmodulin-dependent protein kinase kinase A inhibitor | |||
| 0.06 | 0.045 | 0.06 | Cannabinoid CB1 receptor antagonist | |||
| 0.076 | 0.062 | 0.076 | Phosphodiesterase 3A inhibitor | |||
| 0.038 | 0.03 | 0.038 | 5 Hydroxytryptamine 2B agonist | |||
| 0.052 | 0.044 | 0.052 | Thromboxane synthase inhibitor | |||
| 0.018 | 0.011 | 0.018 | Sodium/hydrogen exchanger inhibitor | |||
| 0.011 | 0.005 | 0.011 | Corticotropin releasing factor antagonist | |||
| 0.061 | 0.055 | 0.12 | Cyclin B3 inhibitor | 0.12 0.021 DBMET00395 | DBMET00395 | |
| 0.056 | 0.051 | 0.056 | 5 Hydroxytryptamine 2A agonist | |||
| 0.073 | 0.069 | 0.073 | Glycine receptor antagonist | |||
| 0.03 | 0.03 | 0.032 | Estrogen-related receptor beta antagonist | 0.031 0.027 DBMET00395 0.032 0.023 DBMET00396 | DBMET00396 | |
| 0.197 | 0.211 | 0.249 | Antiobesity | 0.249 0.158 DBMET00396 | DBMET00396 | |
| 0.078 | 0.098 | 0.086 | Glutamate release inhibitor | 0.086 0.073 DBMET00396 | DBMET00396 | |
| 0.066 | 0.087 | 0.083 | NMDA receptor antagonist | 0.083 0.061 DBMET00396 | DBMET00396 | |
| 0.033 | 0.07 | 0.038 | CF transmembrane conductance regulator antagonist | 0.038 0.032 DBMET00396 | DBMET00396 | |
| 0.141 | 0.224 | 0.183 | RNA-directed DNA polymerase inhibitor | 0.183 0.126 DBMET00396 | DBMET00396 | |
| 0.141 | 0.252 | 0.206 | Immunomodulator | 0.206 0.157 DBMET00396 | DBMET00396 | |
| 0.071 | 0.186 | 0.124 | Cytidine deaminase inhibitor | 0.124 0.096 DBMET00395 | DBMET00395 | |
| 0.1 | 0.385 | 0.276 | Ca2+/calmodulin-dependent kinase II alpha inhibitor | 0.276 0.083 DBMET00395 | DBMET00395 | |
| 0.002 | 0.958 | 0.033 | 1,3-Beta-glucan synthase inhibitor | 0.033 0.009 DBMET00395 | DBMET00395 | Ext | Pa | Pi | Pmax | Activity | Other Results | ID Pa_max |